Opioid and cannabinoid modulation of precipitated withdrawal in δ9-tetrahydrocannabinol and morphine-dependent mice

Journal of Pharmacology and Experimental Therapeutics

Volumn 298, Issue 3, 2001, Pages 1007-1014

  Lichtman, A H ^a   Sheikh, S M ^a   Loh, H H ^b   Martin, B R ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID; CANNABINOID 1 RECEPTOR; MORPHINE; MORPHINE SULFATE; MU OPIATE RECEPTOR; NALOXONE; OPIATE; RIMONABANT; TETRAHYDROCANNABINOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANNABIS ADDICTION; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG DEPENDENCE; DRUG WITHDRAWAL; JUMPING; KNOCKOUT MOUSE; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; TREMOR;

ANIMALS; BEHAVIOR, ANIMAL; CANNABINOIDS; DIARRHEA; DRUG IMPLANTS; HALLUCINOGENS; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; MICE, INBRED ICR; MICE, KNOCKOUT; MORPHINE; MORPHINE DEPENDENCE; NARCOTICS; OPIOID PEPTIDES; PIPERIDINES; PYRAZOLES; RECEPTORS, CANNABINOID; RECEPTORS, DRUG; RECEPTORS, OPIOID, MU; SUBSTANCE WITHDRAWAL SYNDROME; TETRAHYDROCANNABINOL;

EID: 0034893982     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Cannabinoid precipitated withdrawal by the selective cannabinoid receptor antagonist, SR 141716A
2. 9-tetrahydrocannabinol: Studies on precipitated and abrupt withdrawal
3. Dependence on tetrahydrocannabinol in rhesus monkeys
4. Effect of some cannabinoids on naloxone-precipitated abstinence in morphine-dependent mice
5. Inhibition of naloxone-induced withdrawal in morphine dependent mice by 1-trans-delta9-tetrahydrocannabinol
6. Time course of the effects of naturally occurring cannabinoids on morphine abstinence syndrome
7. A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions
8. Relationships between frequency and quantity of marijuana use and last year proxy dependence among adolescents and adults in the United States
9. CB1 receptor antagonist precipitates withdrawal in mice chronically exposed to Δ9-THC
10. Abstinence symptoms following oral THC administration to humans
11. Abstinence symptoms following smoked marijuana in humans
12. Morphine-dependent rats: Blockade of precipitated abstinence by tetrahydrocannabinol
13. 9-tetrahydrocannabinol: Tolerance to the stimulus effects
14. Behavioural and biochemical evidence for signs of abstinence in mice chronically treated with delta-9-tetrahydrocannabinol
15. The 30-day trip - Clinical studies of cannabis tolerance and dependence
16. Clinical studies of cannabis tolerance and dependence
17. Physiological and psychological dependence on the in rhesus monkeys
18. 9-tetrahydrocannabinol-tolerant rats
19. SR 141716A is an inverse agonist at the human cannabinoid CB1 receptor
20. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice
21. Failure to obtain "cannabis-directed behavior" and abstinence syndrome in rats chronically treated with cannabis sativa extracts
22. Effects of SR 141716A after acute or chronic cannabinoid administration in dogs
23. mu Opioid receptor knockout in mice: Effects on ligand-induced analgesia and morphine lethality
24. Self-administration of the cannabinoid receptor agonist WIN 55, 212-2 in drug-naive mice
25. Characteristics of tetrahydrocannabinol tolerance
26. 9-transtetrahydrocannabinol in pigeons: Tolerance to the behavioral effects
27. Transgenic studies of pain
28. 1 cannabinoid receptor antagonist-induced opiate withdrawal in morphine-dependent rats
29. SR 141716A, a potent and selective antagonist of the brain cannabinoid receptor
30. Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal
31. Long-term treatment with SR 141716A, the CB1 receptor antagonist, influences morphine withdrawal syndrome
32. Cannabinoid-precipitated withdrawal: A time-course study of the behavioral aspect and its correlation with cannabinoid receptors and G protein expression
33. 9-tetrahydrocannabinol precipitated by a cannabinoid receptor antagonist
34. Cannabinoid withdrawal syndrome is reduced in pre-proenkephalin knock-out mice
35. Anandamide decreases naloxoneprecipitated withdrawal signs in mice chronically treated with morphine
36. Simultaneous quantitative assessment of morphine-tolerance and physical dependence
37. Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice